

depleted of activity of proteins that bind polyadenylate;

ii) a source of ATP; and

iii) [said] an exogenous target RNA sequence.

In claim 2, lines 4, 2 and 3, please change the occurrences of "turnover" to --  
deadenylation and degradation --.

Please cancel claims 7 and 8.

In claim 9, line 1, please change "8" to -- 1 --.

In claim 21, lines 5 and 6, please change the occurrences of "turnover" to  
-- deadenylation and degradation --.

In claim 27, line 1, please change "turnover" to -- deadenylation and degradation --.

In claim 33, lines 7 and 8, please change both occurrences of "turnover" to --  
deadenylation and degradation --.

Please rewrite claim 38 as follows.

(Amended) The method of claim 36 [33] wherein said determining the extent of  
deadenylation and degradation [turnover] of said target RNA sequence comprises  
determining the extent of degradation of said labeled target RNA.

Please amend claim 46 as follows.

(Amended) A method for identifying an agent capable of modulating regulated [the]  
deadenylation of a target RNA sequence comprising

(A) providing a [the] system that recapitulates regulated RNA deadenylation of  
an exogenously-added preselected target RNA sequence comprising

i) a cytoplasmic extract supernatant from a 100,000 x g, 1 hour  
centrifugation isolated from eukaryotic cells or tissues, said extract  
depleted of activity of proteins that bind polyadenylate;

ii) said target RNA sequence [the system of claim 1 in the absence of a nucleotide triphosphate];

(B) introducing said agent into said system;

(C) monitoring the deadenylation of said target RNA sequence in said system;  
and

(D) identifying an agent able to modulate the extent of said deadenylation as capable of modulating the regulated deadenylation of said target RNA sequence.

B3  
conc'd

In claim 47, line 1, please change "the" to - - regulated - -.

In claim 51, line 6, please change "turnover" to - - deadenylation and degradation - -.

Please amend claim 53 as follows:

53. (Twice Amended) A kit for monitoring the stability of a preselected exogenous target RNA sequence under conditions capable of recapitulating regulated RNA deadenylation and degradation [turnover], said kit comprising:

B4  
sub  
C19

- (a) a cytoplasmic [cell] extract supernatant from a 100,000 x g, 1 hour centrifugation, said extract depleted of activity of proteins that bind polyadenylate;
- (b) other reagents; and
- (c) directions for use of said kit.

#### Remarks

Claims 1, 2 and 4-55 are pending in the application. By way of the foregoing amendment, the subject matter of claims 7 and 8 have been incorporated into claims 1 and 46, the latter which has been rewritten as an independent claim. As a result, claims 1, 2, 4-6 and 9-55 are pending in